PBD Biotech Limited specialises in the use of novel phage-based technology for the detection of tuberculosis and related mycobacterial diseases in the fields of human and veterinary diagnostics.
The company has developed proprietary technology that can be used to detect the presence of mycobacteria such as: Mycobacterium tuberculosis (Human TB), second only to Covid as a fatal infectious disease; Mycobacterium (bovine TB) and Mycobacterium avium subsp. paratuberculosis (MAP; Johne’s disease), which are both significant causes of loss of profitability in the agricultural industry.
The company was co-founded in 2018, by: Prof. Cath Rees, Professor in Microbiology at the University of Nottingham and Chief Scientific Officer at PBD Biotech; Dr Ben Swift, Research Fellow in Antimicrobial Resistance, Royal Veterinary College and Director of Research and Development at PBD Biotech; together with serial entrepreneur Dr Berwyn Clarke.
The registered office is at Grosvenor House, Birmingham, UK.